A notable wave of positive analyst coverage swept over biotech developer Ocugen in March. Market experts are setting price targets significantly above the current trading level, citing accelerated progress in the company’s gene therapy pipeline for rare eye diseases. The early completion of dosing in a pivotal Phase 2/3 trial provides the fundamental basis for this upgraded outlook.
Clinical Progress Drives Optimism
The surge in analyst confidence is directly tied to concrete operational milestones. Ocugen has successfully completed patient dosing ahead of schedule in its registration-enabling Phase 2/3 trial, named GARDian3, for its candidate OCU410ST. This therapy targets Stargardt disease, an inherited form of macular degeneration that currently has no approved treatments in the United States or Europe.
Notably, the company enrolled all 63 trial participants in under nine months. A key factor supporting the program’s advancement is the clean safety profile observed to date, with no reports of serious adverse events or unwanted inflammatory responses in the eye.
Beyond the Stargardt study, Ocugen has also finished patient recruitment for its Phase 3 liMeliGhT trial targeting retinitis pigmentosa. The company’s strategic goal remains the submission of three Biologics License Applications (BLAs) by 2028.
Should investors sell immediately? Or is it worth buying Ocugen?
Financial Backing and Upcoming Catalysts
From a financial perspective, the developer appears well-positioned for the near term. Following a capital raise that garnered $22.5 million in January, the company’s liquidity is expected to fund operations through the fourth quarter of 2026.
The next critical event for evaluating the pipeline is already scheduled. In the third quarter of 2026, Ocugen will conduct an interim analysis of the GARDian3 study once 24 participants have completed the eight-month follow-up period. This data will form the direct foundation for a planned regulatory submission in mid-2027.
Market Analysts Set Ambitious Targets
Several investment firms have recently issued bullish research notes on the stock, reflecting growing conviction in the clinical trajectory:
- Canaccord Genuity: “Buy” rating with a $12.00 price target
- Oppenheimer: “Outperform” rating with a $10.00 price target
- HC Wainwright: “Buy” rating with a $10.00 price target
- Chardan Capital: “Buy” rating with a $7.00 price target
Despite these double-digit price objectives, the equity recently experienced selling pressure, declining approximately 10% over a one-week period to a current level of €1.52. On a year-to-date basis, however, the volatile stock still shows a substantial gain of over 130%.
Ad
Ocugen Stock: Buy or Sell?! New Ocugen Analysis from April 6 delivers the answer:
The latest Ocugen figures speak for themselves: Urgent action needed for Ocugen investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 6.
Ocugen: Buy or sell? Read more here...
